Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 101241654 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-9519 (Electronic) Linking ISSN: 15563650 NLM ISO Abbreviation: Clin Toxicol (Phila) Subsets: MEDLINE
    • بيانات النشر:
      Publication: London : Informa Healthcare
      Original Publication: Philadelphia, PA : Taylor & Francis, c2005-
    • الموضوع:
      COVID-19*/epidemiology ; Cannabinoids*/chemistry ; Drug Overdose*/prevention & control ; Illicit Drugs*/analysis; Benzodiazepines ; Fentanyl ; Humans ; Ontario/epidemiology
    • نبذة مختصرة :
      Background: Toronto's Drug Checking Service (DCS) provides people who use drugs with information on the chemical composition of their substances and conducts real-time monitoring of the unregulated drug supply. Presented are first known data of three newly detected synthetic cannabinoids (SCs) in Toronto, Ontario.
      Methods: The present data are from samples analyzed between April and November 2020. Samples were collected at partnering harm reduction agencies in Toronto and analyzed using gas or liquid chromatography-mass spectrometry. An intake survey queried about the sample characteristics on submission, including expected drug(s).
      Results: Samples were analyzed between 1 April and 20 November 2020 ( N  = 19), which marks the period immediately following imposed COVID-19 border and movement restrictions in Canada. The newly detected, unexpected SCs were ACHMINACA ( n  = 15), AB-FUBINACA ( n  = 3), and 4-fluoro-MDMB-BUTINACA ( n  = 1). Fentanyl was expected in 74% ( n  = 14). Most SCs were detected in samples containing fentanyl or related analogues ( n  = 18; 95%), or benzodiazepine-related drugs (i.e., etizolam and flualprazolam) ( n  = 15; 79%).
      Conclusions: This information can inform overdose prevention efforts and drug market monitoring of SCs in Toronto and regions served by the same drug trafficking routes. The detection of SCs during a period marked by COVID-19-related restrictions can contribute to efforts to identify global drug market trends during this time.
    • Contributed Indexing:
      Keywords: CNS/psychological; analgesics; complications of poisoning; opioids; pharmaceuticals
    • الرقم المعرف:
      0 (Cannabinoids)
      0 (Illicit Drugs)
      12794-10-4 (Benzodiazepines)
      UF599785JZ (Fentanyl)
    • الموضوع:
      Date Created: 20220513 Date Completed: 20220926 Latest Revision: 20221206
    • الموضوع:
      20231215
    • الرقم المعرف:
      10.1080/15563650.2022.2069575
    • الرقم المعرف:
      35546568